Multibagger penny stock under Rs 20 and 1,100 per cent returns: This micro-cap stock bags new order up to Rs 210 crore for lithium carbonate!
Recently, the company secured a three-year supply contract worth more than Rs 175 crore.
Remedium Lifecare Limited has taken significant steps to enter the lithium carbonate market. The company has acquired technology from Angel Partners, Ltd., UK, to manufacture lithium carbonate in India and has signed a supply agreement with Alfa Chemicals and Solvents Ltd., Turkey. The supply of technical-grade lithium carbonate, crucial for lithium-ion batteries, is set to commence in the fourth quarter of FY 2024-25. The annual supply value for CY 2025 is estimated between Rs 167 crore and Rs 210 crore.
Remedium plans to collaborate with contract manufacturers to produce technical-grade lithium carbonate utilizing the acquired technology. These strategic moves position Remedium as a key player in the growing lithium-ion battery market.
Earlier, Remedium Lifecare Limited secured a three-year supply contract valued at over Rs. 175 crore from Aster Biotech Limited, UK. The contract encompasses the supply of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
Remedium Lifecare Limited is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products. The company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets. The shares of Remedium Lifecare Limited have also delivered multibagger returns of over 1,100 per cent in the last three years. It is also worth to note that the stock looks weak on technofunda basis.
Disclaimer: The article is for informational purposes only and not investment advice.